Albumin Market

Albumin Market (Product Type: Human Serum Albumin and Recombinant Albumin; Application and End-user) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Albumin Market Outlook 2031

  • The global market was valued at US$ 4.6 Bn in 2020
  • It is estimated to expand at a CAGR of 6.1% from 2021 to 2031
  • The global albumin industry is expected to reach the value of US$ 8.1 Bn by the end of 2031

Analysts’ Viewpoint on Albumin Market Scenario

In order to emerge resilient to the COVID-19 outbreak, companies in the global market for albumin are expected to adopt contingency planning across departments to revive organizational revenue and capital expenditure. Extraction of recombinant human serum albumin and processing incur significant cost & expertise. Additionally, it requires expert staff to handle operations, as the recombinant technology attracts stringent laws and regulations. Moreover, cost associated with refinement of recombinant albumin to attain high purity is a major concern among the industry players. This acts as a major restraint for the global market. Hence, companies should work closely with governments in developed economies of North America and Europe to employ supportive regulatory policies that help to lower the cost of albumin production. They should diversify business activities in developing economies such as India and China to capitalize on value-grab opportunities.

Rise in Investments for Life Sciences Catalyzing Demand for Albumin Market

Geographically, North America and Europe are projected to be highly attractive markets for albumin during the forecast period. A rise in investments in life sciences by a large number of biopharmaceutical companies and research institutes is expected to boost the global market for albumin in these regions throughout the assessment period.

The demand for albumin is high in countries such as India and China. However, the uptake of these therapeutics is low due to the lack of awareness about these products and their therapeutic uses. Hence, awareness programs conducted by healthcare organizations which include International Plasma Awareness Week, to help increase awareness about plasma donation and the different plasma protein therapies available, along with their potential uses are expected to increase the demand for these therapeutics in treating various conditions.

Improvements in Business Flow amid COVID-19 Outbreak Benefitting Manufacturers

Companies in the albumin market are maintaining optimum inventory levels to cater to mission-critical projects in the healthcare industry amid the ongoing coronavirus pandemic. Different regions of the world are showing signs that supply chains are recovering as the production & movement of goods are speeding up. Manufacturers based in the Western Hemisphere have been making significant progress in the past few years to secure themselves against volatility in supply from Asia, China in particular, by moving the bulk production to their respective countries.

Chemically-defined Albumin Holds Promising Potentials for Vaccine Innovation

Companies in the albumin market are launching chemically defined, blood and plant hydrolysate-free cell culture media for vaccine manufacturing that outperforms popular VERO media by enabling robust VERO cell expansion and production of difficult-to-express virus types.

Albumin is being widely used as a versatile drug carrier in systems such as albumin fusion protein, albumin-drug nanoparticles, and pro-drugs. It is used as a drug carrier for the treatment of various diseases such as rheumatoid arthritis, diabetes, cancer, and hepatitis.

It also has the ability to bind to an extraordinarily diverse range of molecules, as it provides a depository for various compounds. These factors make albumin most suitable to be used as an excipient in vaccine and drug production.

Technological Advancements Help Overcome High-Cost Development of Albumin Therapeutics

An increase in the usage of albumin as a multifunctional excipient, a shift toward the usage of recombinant albumin, and a grant of regulatory approvals are key factors that are driving the albumin market. However, the high cost & expertise required to set up production plants and stringent regulatory criteria are restraining the growth rate of the market. Nevertheless, emerging markets such as India, China, Brazil, and South Africa present significant opportunities in the global market, owing to growing contract research manufacturing. Such findings are helping stakeholders in the global market for albumin to diversify their business activities in regions where regulatory standards are comparatively easier to adhere to.

Technological developments in drug formulation & drug delivery and an increase in access to technologies such as the use of albumin in cell culture media present lucrative opportunities for investors. Hence, investments by manufacturers in these developing markets, an increase in contract research manufacturing, and a rise in demand & awareness among end users are expected to boost the growth of the global market.

High Prevalence of Life-threatening Disorders Augmenting Demand for Albumin

In terms of product, the human serum albumin segment is anticipated to account for a major market share of approximately 80%, in terms of revenue, during the forecast period. The growth of the segment can be attributed to the increase in the prevalence of life-threatening disorders & conditions, especially liver diseases, infections, and cardiac surgeries leading to hypoalbuminemia. Other factors driving the segment include the rise in the adoption of albumin products and an increase in the usage of non-therapeutic applications across the world.

Based on application, drug delivery is expected to be the most attractive segment during the forecast period. Collaboration between pharmaceutical and biotechnology companies for the use of recombinant albumin-based drug delivery systems is likely to propel the growth of the segment. In terms of end-user, the pharmaceutical & biotechnology industry segment is expected to dominate the market throughout the assessment period. The segment was valued at US$ 500 Mn in 2017. The rise in research and developmental (R&D) activities for the development of technologically advanced products and an increase in government funding are attributed to the growth of the segment.

Albumin Industry: Overview

  • According to Transparency Market Research’s latest report on the global albumin market for the historical period 2017–2019 and the forecast period from 2021 to 2031, a rise in government support, an increase in research funding, technological advancements, an improved regulatory framework, and a surge in prevalence of chronic liver & kidney diseases are projected to drive the global albumin industry during the forecast period

Increase in Use of Albumin as Multifunctional Excipient: Key Driver

  • Albumin is a protein that is abundant in blood and is necessary for blood osmotic pressure regulation
  • It protects proteins from oxidation by acting as a powerful antioxidant that prevents protein therapeutics from being modified. It also acts as a blocking agent to prevent non-specific adsorption to glass and plastic surfaces and prevents aggregation of protein products during manufacturing and delivery.
  • In the past several years, hypoalbuminemia has become more frequent across the world owing to a surge in the incidence of life-threatening disorders and ailments, such as heart disease and liver disease. Additionally, an increase in acceptance of albumin products, a rise in recognition of recombinant albumin, and a growing emphasis on non-therapeutic applications of albumin across multiple regions contribute to the growth of the global albumin market.

Shift toward Use of Recombinant Albumin: Major Driver

  • Recombinant albumin has emerged as a suitable product for use as an excipient in the manufacture of bio-therapeutics in order to overcome these challenges
  • In addition to preventing the spread of serum-derived disease agents, it provides benefits such as improved batch-to-batch consistency and breaking reliance on increasingly unpredictable supply chains
  • The grant of approvals by national regulatory authorities for novel recombinant albumin products developed by pharmaceutical and biotechnology organizations drives the global albumin market. Moreover, in January 2022, Bio Products Laboratory (BPL), a U.K.-based prominent manufacturer of plasma protein therapies, announced that the National Medical Products Administration (NMPA) granted the company a license to commercialize ALBUMINEX 25% product in China.

High Cost and Expertise Required to Set Up Albumin Production Plants

  • Extraction and processing of recombinant human serum albumin are time-consuming and expensive. Moreover, recombinant technology is subject to strict laws and regulations. Hence, it necessitates the use of expert personnel to manage operations.
  • The cost of refining recombinant albumin to achieve high purity is a major concern among industry players. This acts as a significant restraint on the market.

Albumin Market: Competition Landscape

  • This report profiles major players in the global albumin industry based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global albumin industry is quite competitive, with the top ten players accounting for a major share of the market and companies focusing on research & development to produce better pharmaceutical and vaccine products for the existing diseases
  • Leading players operating in the global albumin business are
    • Albumin Therapeutics, LLC
    • Albumedix A/S
    • CSL Behring LLC
    • Biotest AG
    • SeraCare Life Sciences (LGC)
    • HiMedia Laboratories Pvt. Ltd.
    • Grifols International, S.A.
    • Medxbio Pte Ltd.
    • InVitria
    • RayBiotech, Inc.
    • Takeda Pharmaceutical Company Limited (Shire)
    • Octapharma AG
    • Sigma-Aldrich Co. (Merck KGaA)

Albumin Market: Key Developments

  • Leading players in the global market are engaged in regulatory approvals, technologically advanced products, the launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to drive the global market. A few expansion strategies adopted by players operating in the global albumin business are:
    • In November 2021, Grifols announced the release of its latest albumin portfolio innovation, ALBUTEIN FlexBag. It is a versatile container that allows for easy storage and greater convenience, as it does not require vented infusion sets or filters.
    • In July 2021, Grifols, a global leader in the production of plasma-derived medicines, partnered with the U.S. firm ImmunoTek Bio Centers LLC to build plasma centers
    • In April 2021, Albumedix announced the expansion of its research collaboration with Cobra Biologics, the gene therapy division of Charles River Laboratories International, Inc., and Cognate BioServices
    • In March 2021, Albumedix Ltd., a provider of advanced therapies and a world leader in recombinant human albumin (rHA), entered into a distribution agreement with FUJIFILM Wako Pure Chemical Corporation, an established and well-known reagent supplier
    • In July 2020, the European Medicines Agency (EMA), an agency of the European Union in charge of the evaluation and supervision of medicinal products, approved CSL Behring’s long-acting and novel Idelvion, a recombinant albumin fusion protein, in order to treat hemophilia B
    • In May 2020, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, introduced ALBUMINEX 5 percent (human albumin) solution and ALBUMINEX 25 percent for the treatment of hypovolemia, ascites, and hypoalbuminemia
  • The report on the global albumin market discusses individual strategies followed by company profiles of manufacturers of albumin devices. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global market for albumin.

Albumin Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 4.6 Bn

Market Forecast Value in 2031

US$ 8.1 Bn

Growth Rate (CAGR)

6.1%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross-segment analysis at the global as well as regional levels. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and a parent industry overview.

Competition Landscape

  • Market share analysis by the company (2020)
  • Company profiles section includes an overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product Type
    • Human Serum Albumin
    • Recombinant Albumin
  • Application
    • Human Serum Albumin Applications
      • Drug Delivery
      • Drug Formulation
      • Medical Device Coating
      • Vaccines
      • Culture Medium & Stabilizer
      • In Vitro Fertilization
      • Diagnostics
    • Recombinant Albumin Applications
      • Drug Delivery
      • Drug Formulation
      • Medical Device Coating
      • Vaccines
      • Culture Medium & Stabilizer
      • In Vitro Fertilization
      • Diagnostics
  • End-user
    • Pharmaceutical & Biotechnology Companies
    • Research Institutes
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • U.K.
  • Germany
  • Italy
  • France
  • China
  • Spain
  • Japan
  • India
  • Australia & New Zealand
  • South Korea
  • Mexico
  • Brazil
  • South Africa
  • GCC Countries

Companies Profiled

  • Albumedix A/S (Novozyme A/S)
  • CSL Behring LLC
  • Biotest AG
  • Albumin Therapeutics, LLC
  • Grifols International, S.A.
  • HiMedia Laboratories Pvt. Ltd.
  • InVitria
  • Medxbio Pte Ltd.
  • Octapharma AG
  • RayBiotech, Inc.
  • SeraCare Life Sciences (LGC)
  • Sigma-Aldrich Co. (Merck KGaA)
  • Takeda Pharmaceutical Company Limited (Shire)
  • Other Prominent Players

Customization Scope

Available upon request

Pricing

Available upon request

Albumin Market – Segmentation

Product Type
  • Human Serum Albumin
  • Recombinant Albumin
Application
  • Human Serum Albumin Applications
    • Drug Formulation
    • Drug Delivery
    • Vaccines
    • Medical Device Coating
    • Culture Medium & Stabilizer
    • Diagnostics
    • In Vitro Fertilization
  • Recombinant Albumin Applications
    • Drug Formulation
    • Drug Delivery
    • Vaccines
    • Medical Device Coating
    • Culture Medium & Stabilizer
    • Diagnostics
    • In Vitro Fertilization
End-user
  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market value of albumin?

The albumin market is expected to reach the value of US$ 8.1 Bn by the end of 2031

What is the anticipated CAGR of the global market for albumin in the forecast period?

The global market is estimated to expand at a CAGR of 6.1% from 2021 to 2031

What are the key driving factors for the growth of the albumin industry?

The market is driven by an increase in the use of albumin to treat hypoalbuminemia in patients with chronic injuries

Which region is expected to project the highest market share in the global market?

North America accounted for a major share of the global market, owing to an increase in demand for albumin in clinical research activities

Who are the key players in the global albumin business?

Key players in the global market for albumin include Biotest AG, CSL Behring LLC, HiMedia Laboratories Pvt. Ltd., Grifols International, S.A., Medxbio Pte Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Albumin Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Albumin Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)

        5.2. Regulatory Scenario by Key Countries

        5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    6. Global Albumin Market Analysis and Forecast, by Product

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Product, 2017–2031

            6.3.1. Human Serum Albumin

            6.3.2. Recombinant Albumin

        6.4. Market Attractiveness Analysis, by Product

    7. Global Albumin Market Analysis and Forecasts, by Application

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Application, 2017–2031

            7.3.1. Human Serum Albumin Applications

                7.3.1.1. Drug Formulation

                7.3.1.2. Drug Delivery

                7.3.1.3. Vaccines

                7.3.1.4. Medical Device Coating

                7.3.1.5. Culture Media & Stabilizers

                7.3.1.6. Diagnostics

                7.3.1.7. In Vitro Fertilization

            7.3.2. Recombinant Albumin Applications

                7.3.2.1. Drug Formulation

                7.3.2.2. Drug Delivery

                7.3.2.3. Vaccines

                7.3.2.4. Medical Device Coating

                7.3.2.5. Culture Media & Stabilizers

                7.3.2.6. Diagnostics

                7.3.2.7. In Vitro Fertilization

    8. Global Albumin Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by End-user, 2017–2031

            8.3.1. Pharmaceutical & Biotechnology Companies

            8.3.2. Research Institutes

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by End-user

    9. Global Albumin Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Albumin Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Product, 2017–2031

            10.2.1. Human Serum Albumin

            10.2.2. Recombinant Albumin

        10.3. Market Value Forecast, by Application, 2017–2031

            10.3.1. Human Serum Albumin Applications

                10.3.1.1. Drug Formulation

                10.3.1.2. Drug Delivery

                10.3.1.3. Vaccines

                10.3.1.4. Medical Device Coating

                10.3.1.5. Culture Media & Stabilizers

                10.3.1.6. Diagnostics

                10.3.1.7. In Vitro Fertilization

            10.3.2. Recombinant Albumin Applications

                10.3.2.1. Drug Formulation

                10.3.2.2. Drug Delivery

                10.3.2.3. Vaccines

                10.3.2.4. Medical Device Coating

                10.3.2.5. Culture Media & Stabilizers

                10.3.2.6. Diagnostics

                10.3.2.7. In Vitro Fertilization

        10.4. Market Value Forecast, by End-user, 2017–2031

            10.4.1. Pharmaceutical & Biotechnology Companies

            10.4.2. Research Institutes

            10.4.3. Others

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Product

            10.6.2. By Application

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Albumin Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product, 2017–2031

            11.2.1. Human Serum Albumin

            11.2.2. Recombinant Albumin

        11.3. Market Value Forecast, by Application, 2017–2031

            11.3.1. Human Serum Albumin Applications

                11.3.1.1. Drug Formulation

                11.3.1.2. Drug Delivery

                11.3.1.3. Vaccines

                11.3.1.4. Medical Device Coating

                11.3.1.5. Culture Media & Stabilizers

                11.3.1.6. Diagnostics

                11.3.1.7. In Vitro Fertilization

            11.3.2. Recombinant Albumin Applications

                11.3.2.1. Drug Formulation

                11.3.2.2. Drug Delivery

                11.3.2.3. Vaccines

                11.3.2.4. Medical Device Coating

                11.3.2.5. Culture Media & Stabilizers

                11.3.2.6. Diagnostics

                11.3.2.7. In Vitro Fertilization

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Pharmaceutical & Biotechnology Companies

            11.4.2. Research Institutes

            11.4.3. Others

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Product

            11.6.2. By End-user

            11.6.3. By Country/Sub-region

    12. Asia Pacific Albumin Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product, 2017–2031

            12.2.1. Human Serum Albumin

            12.2.2. Recombinant Albumin

        12.3. Market Value Forecast by Application, 2017–2031

            12.3.1. Human Serum Albumin Applications

                12.3.1.1. Drug Formulation

                12.3.1.2. Drug Delivery

                12.3.1.3. Vaccines

                12.3.1.4. Medical Device Coating

                12.3.1.5. Culture Media & Stabilizers

                12.3.1.6. Diagnostics

                12.3.1.7. In Vitro Fertilization

            12.3.2. Recombinant Albumin Applications

                12.3.2.1. Drug Formulation

                12.3.2.2. Drug Delivery

                12.3.2.3. Vaccines

                12.3.2.4. Medical Device Coating

                12.3.2.5. Culture Media & Stabilizers

                12.3.2.6. Diagnostics

                12.3.2.7. In Vitro Fertilization

        12.4. Market Value Forecast, by Product, 2017–2031

            12.4.1. Pharmaceutical & Biotechnology Companies

            12.4.2. Research Institutes

            12.4.3. Others

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. South Korea

            12.5.4. India

            12.5.5. Australia & New Zealand

            12.5.6. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Product

            12.6.2. By Application

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Albumin Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product, 2017–2031

            13.2.1. Human Serum Albumin

            13.2.2. Recombinant Albumin

        13.3. Market Value Forecast by Application, 2017–2031

            13.3.1. Human Serum Albumin Applications

                13.3.1.1. Drug Formulation

                13.3.1.2. Drug Delivery

                13.3.1.3. Vaccines

                13.3.1.4. Medical Device Coating

                13.3.1.5. Culture Media & Stabilizers

                13.3.1.6. Diagnostics

                13.3.1.7. In Vitro Fertilization

            13.3.2. Recombinant Albumin Applications

                13.3.2.1. Drug Formulation

            13.3.3. Drug Delivery

                13.3.3.1. Vaccines

                13.3.3.2. Medical Device Coating

                13.3.3.3. Culture Media & Stabilizers

                13.3.3.4. Diagnostics

                13.3.3.5. In Vitro Fertilization

        13.4. Market Value Forecast, by End-user, 2017–2031

            13.4.1. Pharmaceutical & Biotechnology Companies

            13.4.2. Research Institutes

            13.4.3. Others

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Product

            13.6.2. By Application

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Albumin Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Product, 2017–2031

            14.2.1. Human Serum Albumin

            14.2.2. Recombinant Albumin

        14.3. Market Value Forecast, by End-user, 2017–2031

            14.3.1. Pharmaceutical & Biotechnology Companies

            14.3.2. Research Institutes

            14.3.3. Others

        14.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.4.1. GCC Countries

            14.4.2. South Africa

            14.4.3. Rest of Middle East & Africa

        14.5. Market Attractiveness Analysis

            14.5.1. By Product

            14.5.2. By Application

            14.5.3. By End-user

            14.5.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2020

        15.3. Company Profiles

            15.3.1. Albumedix A/S

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Financial Analysis

                15.3.1.3. Growth Strategies

                15.3.1.4. SWOT Analysis

            15.3.2. Albumin Therapeutics, LLC

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Financial Analysis

                15.3.2.3. Growth Strategies

                15.3.2.4. SWOT Analysis

            15.3.3. Biotest AG

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Financial Analysis

                15.3.3.3. Growth Strategies

                15.3.3.4. SWOT Analysis

            15.3.4. CSL Behring LLC

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Financial Analysis

                15.3.4.3. Growth Strategies

                15.3.4.4. SWOT Analysis

            15.3.5. Grifols International, S.A.

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Financial Analysis

                15.3.5.3. Growth Strategies

                15.3.5.4. SWOT Analysis

            15.3.6. HiMedia Laboratories Pvt. Ltd.

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Financial Analysis

                15.3.6.3. Growth Strategies

                15.3.6.4. SWOT Analysis

            15.3.7. InVitria

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Financial Analysis

                15.3.7.3. Growth Strategies

                15.3.7.4. SWOT Analysis

            15.3.8. Medxbio Pte Ltd.

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Financial Analysis

                15.3.8.3. Growth Strategies

                15.3.8.4. SWOT Analysis

            15.3.9. Octapharma AG

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Financial Analysis

                15.3.9.3. Growth Strategies

                15.3.9.4. SWOT Analysis

            15.3.10. RayBiotech, Inc.

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Financial Analysis

                15.3.10.3. Growth Strategies

                15.3.10.4. SWOT Analysis

            15.3.11. Seracare Life Sciences (LGC)

                15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.11.2. Financial Analysis

                15.3.11.3. Growth Strategies

                15.3.11.4. SWOT Analysis

                15.3.11.5. SWOT Analysis

            15.3.12. Sigma-Aldrich Co. (Merck KGaA)

                15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.12.2. Financial Analysis

                15.3.12.3. Growth Strategies

                15.3.12.4. SWOT Analysis

            15.3.13. Takeda Pharmaceutical Company Limited (Shire)

                15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.13.2. Financial Analysis

                15.3.13.3. Growth Strategies

                15.3.13.4. SWOT Analysis

    List of Tables

    Table 01: Global Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 02: Global Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 03: Global Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031

    Table 04: Global Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

    Table 05: Global Albumin Market Value (US$ Mn), Forecast, 2017–2031

    Table 06: Global Albumin Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 07: North America Albumin Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 08: North America Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 09: North America Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 10: North America Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031

    Table 11: North America Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

    Table 12: North America Albumin Market Value (US$ Mn), Forecast, by End-user, 2017–2031

    Table 13: Europe Albumin Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

    Table 14: Europe Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 15: Europe Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 16: Europe Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031

    Table 17: Europe Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

    Table 18: Europe Albumin Market Value (US$ Mn), Forecast, by End-user, 2017–2031

    Table 19: Asia Pacific Albumin Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

    Table 20: Asia Pacific Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 21: Asia Pacific Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 22: Asia Pacific Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031

    Table 23: Asia Pacific Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

    Table 24: Asia Pacific Albumin Market Value (US$ Mn), Forecast, 2017–2031

    Table 25: Latin America Albumin Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

    Table 26: Latin America Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 27: Latin America Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 28: Latin America Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031

    Table 29: Latin America Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

    Table 30: Latin America Albumin Market Value (US$ Mn), Forecast, 2017–2031

    Table 31: Middle East & Africa Albumin Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

    Table 32: Middle East & Africa Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 33: Middle East & Africa Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 34: Middle East & Africa Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031

    Table 35: Middle East & Africa Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

    Table 36: Middle East & Africa Albumin Market Value (US$ Mn), Forecast, 2017–2031

    List of Figures

    Figure 01: Global Albumin market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Albumin market Value Share, by Product Type, 2020

    Figure 03: Global Albumin market Value Share, by End-user, 2020

    Figure 04: Global Albumin market Value Share, by Region, 2020

    Figure 05: Global Albumin Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 06: Global Albumin Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 07: Global Albumin Market Revenue (US$ Mn), by Human Serum Albumin, 2017–2031

    Figure 08: Global Albumin Market Revenue (US$ Mn), by Recombinant Albumin, 2017–2031

    Figure 09: Global Albumin Market Value Share Analysis, by Application, 2020 and 2031

    Figure 10: Global Albumin Market Attractiveness Analysis, by Application, 2021–2031

    Figure 11: Global Albumin Market Revenue (US$ Mn), by Human Serum Albumin Applications, 2017–2031

    Figure 12: Global Albumin Market Revenue (US$ Mn), by Recombinant Albumin Applications, 2017–2031

    Figure 13: Global Albumin Market, by End-user, 2020 and 2031

    Figure 14: Global Albumin Market, by End-user, 2021–2031

    Figure 15: Global Albumin Market (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017–2031

    Figure 16: Global Albumin Market (US$ Mn), by Research Institutes, 2017–2031

    Figure 17: Global Albumin Market (US$ Mn), by Others, 2017–2031

    Figure 18: Global Albumin Market Value Share Analysis, by Region, 2020 and 2031

    Figure 19: Global Albumin Market Attractiveness Analysis, by Region, 2021–2031

    Figure 20: North America Albumin Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 21: North America Albumin Market Value Share Analysis, by Country, 2020 and 2031

    Figure 22: North America Albumin Market Attractiveness Analysis, by Country, 2021–2031 

    Figure 23: North America Albumin Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 24: North America Albumin Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 25: North America Albumin Market Value Share Analysis, by Application, 2020 and 2031

    Figure 26: North America Albumin Market Attractiveness Analysis, by Application, 2021–2031

    Figure 27: North America Albumin Market, by End-user, 2020 and 2031

    Figure 28: North America Albumin Market, by End-user, 2021–2031

    Figure 29: Europe Albumin Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

    Figure 30: Europe Albumin Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 31: Europe Albumin Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 32: Europe Albumin Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 33: Europe Albumin Market Value Share Analysis, by Application, 2020 and 2031

    Figure 34: Europe Albumin Market Attractiveness Analysis, by Application, 2021–2031

    Figure 35: Europe Albumin Market, by End-user, 2020 and 2031

    Figure 36: Europe Albumin Market, by End-user, 2021–2031

    Figure 37: Asia Pacific Albumin Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

    Figure 38: Asia Pacific Albumin Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 39: Asia Pacific Albumin Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 40: Asia Pacific Albumin Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 41: Asia Pacific Albumin Market Value Share Analysis, by Application, 2020 and 2031

    Figure 42: Asia Pacific Albumin Market Attractiveness Analysis, by Application, 2021–2031

    Figure 43: Asia Pacific Albumin Market, by End-user, 2020 and 2031

    Figure 44: Asia Pacific Albumin Market, by End-user, 2021–2031

    Figure 45: Latin America Albumin Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

    Figure 46: Latin America Albumin Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 47: Latin America Albumin Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 48: Latin America Albumin Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 49: Latin America Albumin Market Value Share Analysis, by Application, 2020 and 2031

    Figure 50: Latin America Albumin Market Attractiveness Analysis, by Application, 2021–2031

    Figure 51: Latin America Albumin Market, by End-user, 2020 and 2031

    Figure 52: Latin America Albumin Market, by End-user, 2021–2031

    Figure 53: Middle East & Africa Albumin Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 54: Middle East & Africa Albumin Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

    Figure 55: Middle East & Africa Albumin Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 56: Middle East & Africa Albumin Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 57: Middle East & Africa Albumin Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 58: Middle East & Africa Albumin Market Value Share Analysis, by Application, 2020 and 2031

    Figure 59: Middle East & Africa Albumin Market Attractiveness Analysis, by Application, 2021–2031

    Figure 60: Middle East & Africa Albumin Market, by End-user, 2020 and 2031

    Figure 61: Middle East & Africa Albumin Market, by End-user, 2021–2031

    Figure 62: Global Albumin Market Share, by Company, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved